Evidence map›Paper›PMID 20398344›Full record

ArticleNutrition & metabolism2010

Role of carnitine in disease.

Judith L Flanagan, Peter A Simmons, Joseph Vehige, Mark Dp Willcox, Qian Garrett

Open access · goldAbstract read
In one paragraph

Article in Nutrition & metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 276 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
276citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

276 citing papers in PubMed, 3 syntheses or guidelines pooled it, 606 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Maternal obesity results in decreased syncytiotrophoblast synthesis of palmitoleic acid, a fatty acid with anti-inflammatory and insulin-sensitizing properties.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Amino acid metabolism in diabetic kidney disease.Clinical and experimental nephrology · 2026
    Review
  18. Fluorinated Carnitine Derivatives as Tools to Visualise Carnitine Transport and Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  19. Article
  20. Review

216 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Judith L FlanaganInstitute for Eye Research, Sydney, New South Wales, Australia. j.flanagan@ier.org.au.
Peter A Simmons
Joseph Vehige
Mark Dp Willcox
Qian Garrett
Allergan (United States) · USUNSW Sydney · AUBrien Holden Vision Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnitine is a conditionally essential nutrient that plays a vital role in energy production and fatty acid metabolism. Vegetarians possess a greater bioavailability than meat eaters. Distinct deficiencies arise either from genetic mutation of carnitine transporters or in association with other disorders such as liver or kidney disease. Carnitine deficiency occurs in aberrations of carnitine regulation in disorders such as diabetes, sepsis, cardiomyopathy, malnutrition, cirrhosis, endocrine disorders and with aging. Nutritional supplementation of L-carnitine, the biologically active form of carnitine, is ameliorative for uremic patients, and can improve nerve conduction, neuropathic pain and immune function in diabetes patients while it is life-saving for patients suffering primary carnitine deficiency. Clinical application of carnitine holds much promise in a range of neural disorders such as Alzheimer's disease, hepatic encephalopathy and other painful neuropathies. Topical application in dry eye offers osmoprotection and modulates immune and inflammatory responses. Carnitine has been recognized as a nutritional supplement in cardiovascular disease and there is increasing evidence that carnitine supplementation may be beneficial in treating obesity, improving glucose intolerance and total energy expenditure.

Identifiers

PMID20398344
PMCPMC2861661
OpenAlexW2084023408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.